Background: Decompressive craniectomy (DC) and intracranial pressure (ICP) monitoring are common approaches to reduce the death rate of Traumatic brain injury (TBI) patients, but the outcomes of these patients are unfavorable, particularly those who receive bilateral DC. The authors discuss their experience using ICP and other potential methods to improve the outcomes of TBI patients who receive bilateral DC. Methods: Data from TBI patients receiving bilateral DC from Jan. 2008 to Jan. 2022 were collected via a retrospective chart review. Included patients who received unplanned contralateral DC after initial surgery were identified as unplanned secondary surgery (USS) patients. Patients’ demographics and baseline medical status; pre-, intra-, and postoperative events; and follow-up visit outcome data were analyzed. Results: A total of 151 TBI patients were included. Patients who underwent USS experienced more severe outcomes as assessed using the 3-month modified Rankin Scale score (P = 0.024). In bilateral DC TBI patients, USS were associated with worsen outcomes, moreover, ICP monitoring was able to lower their death rate and was associated with a lower USS incidence. In USS patients, ICP monitoring was not associated with improved outcomes but was able to lower their mortality rate (2/19, 10.5%, vs. 10/25, 40.0%; P = 0.042). Conclusion: The avoidance of USS may be associated with improved outcomes of TBI patients who underwent bilateral DC. ICP monitoring was a potential approach to lower USS rate in TBI patients, but its specific benefits were uncertain.
29 December 2025 in European Journal of Medical Research
Brain and central nervous system (CNS) cancers, though relatively rare, contribute substantially to neurological disability and cancer-related mortality wo
Timely and accurate triage of acute ischemic stroke patients remains a critical challenge in clinical practice, particularly across heterogeneous imaging protocols and multicenter settings. Existing approaches often focus on isolated tasks such as large-vessel occlusion detection, collateral scoring, or infarct segmentation, leading to fragmented pipelines with limited generalizability and increased latency. In this work, we introduce a unified multimodal framework that jointly integrates non-contrast CT, CT angiography, and CT perfusion under a single encoder-decoder architecture. The system employs symmetry-aware encoders, graph-based vascular modeling, and spatio-temporal fusion, followed by multi-task heads for detection, grading, and segmentation. Trained and validated on multicenter datasets, the framework demonstrates consistent gains over state-of-the-art baselines: AUC improvements of up to +0.05 for LVO detection, a +0.11 increase in quadratic-weighted κ for collateral scoring, and a +5% Dice improvement with reduced volume error for infarct delineation. Beyond technical metrics, the model achieves clinically relevant impact by reducing mis-triage and unnecessary transfers while lowering inference time to under one minute in real-world PACS deployment. Ablation studies further confirm the synergistic benefit of multi-task optimization, which narrows the generalization gap and enhances robustness across unseen centers. Taken together, these results highlight the potential of unified multimodal learning to support fast, reliable, and scalable decision-making in acute stroke care.
Background: Cerebral microbleeds (CMBs) are small chronic brain hemorrhages that can be linked to cognitive decline and stroke risk. Understanding the underlying genetic and proteomic mechanisms can enhance therapeutic interventions. This study aimed to explore the relationship between circulating proteins (cis‐pQTLs) and CMBs using Mendelian randomization (MR) and colocalization analysis, along with protein–protein interaction (PPI) network construction and the evaluation of lifestyle factors influencing CMB‐related proteins. Methods: A two‐sample MR approach was employed to investigate potential causal relationships between protein levels and CMB risk using cis‐pQTLs as instrumental variables. Colocalization analysis was conducted to assess whether the same genetic variants influence both circulating proteins and CMB susceptibility. Additionally, a PPI network was built to prioritize therapeutic targets, and drug efficacy was evaluated using known protein targets. A systematic MR analysis examined the impact of 17 healthy lifestyle factors on CMB‐related proteins. Results: MR analysis revealed an association between 79 plasma proteins and CMBs, with one protein remaining significant after false discovery rate correction. Colocalization analysis identified APOE as a causal protein for CMBs, supported by a strong posterior probability (PP4 = 0.996). PPI network analysis highlighted the potential bleeding risks of antithrombotic medications in CMB pathogenesis and Rosuvastatin. Furthermore, MR analysis showed that dietary factors, particularly cooked vegetable intake, were associated with APOE‐related pathways, though these findings warrant cautious interpretation regarding lifestyle modifications. Conclusions: This study provides evidence for a causal relationship between circulating proteins and CMBs, with APOE identified as a key factor. The identification of coagulation‐related proteins highlights the potential risks of antithrombotic medications in CMB pathogenesis. Lifestyle factors may influence protein‐mediated CMB risk, suggesting avenues for future research into gene–environment interactions.
Background: Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) central nervous system (CNS) infections represent a major therapeutic challenge in neurosurgical patients. Intraventricular or intrathecal polymyxin B sulfate (PMB) is commonly used as salvage therapy but is limited by substantial neurotoxicity. Ceftazidime–avibactam (CZA) exhibits potent in vitro activity against KPC-Kp; however, prospective clinical and pharmacokinetic evidence supporting its use in CNS infections remains limited. Methods: In this prospective, single-centre observational study, adult neurosurgical patients with culture-confirmed KPC-Kp CNS infections admitted to the neurointensive care unit of Huashan Hospital were enrolled. Patients received either intravenous CZA (CZA group, n = 15) or intrathecal/intraventricular PMB-based therapy (PMB group, n = 10). Primary outcomes included clinical cure, microbiological eradication, 28-day mortality, and safety. Therapeutic drug monitoring was performed to determine steady-state plasma and cerebrospinal fluid (CSF) concentrations of ceftazidime, avibactam, and polymyxin B, enabling assessment of CSF penetration and exposure–toxicity relationships. Results: Overall clinical cure and microbiological eradication rates were 68.0% and 84.0%, respectively, with a 28-day mortality of 20.0%. Compared with PMB, CZA was associated with a significantly higher clinical cure rate (86.7% vs. 40.0%, p = 0.024) and a numerically higher eradication rate (93.3% vs. 70.0%). No neurological adverse events occurred in the CZA group, whereas neurological toxicity was observed in 60.0% of PMB-treated patients (p < 0.001). Functional outcomes favoured the CZA group, with lower modified Rankin Scale scores at discharge and at 6 months. Pharmacokinetic analyses demonstrated that steady-state CSF concentrations of ceftazidime and avibactam exceeded commonly accepted pharmacodynamic targets, while markedly elevated PMB CSF concentrations were observed in patients with neurological toxicity. Conclusions: While intravenous CZA showed potentially favourable efficacy and safety compared with local PMB in this cohort, these preliminary findings should be interpreted as hypothesis-generating given the small sample size and non-randomised design. These results provide a rationale for further validation in larger multicentre, randomised controlled trials.
18 May 2026 in Journal of Thrombosis and Thrombolysis